headache
HEADACHE
Headache is a very common problem presenting to primary care physicians and neurologists.
Most headaches are diagnosed based on the history & physical exam w/ no imaging or laboratory examination necessary.
Other types of headaches such as secondary headaches may require further evaluation & referral to a specialist.
Drug Information

Indication: HTN.

Indication: Prophylaxis of migraine w/ or w/o aura. Symptomatic treatment of vestibular vertigo, due to a diagnosed functi...

Indication: Maintenance therapy for symptoms of cerebrovascular origins, labyrinthine & peripheral-circulatory disorde...

Indication: Monotherapy in patients w/ newly diagnosed epilepsy or for conversion to monotherapy in patients w/ epilepsy. ...

Dosage: HTN 50-100 mg daily as a single dose. Arrhythmia Oral maintenance: 50-100 mg/day as a single dose. Angina 50 m

Indication: Inflammatory & degenerative forms of rheumatism: RA, juvenile RA, ankylosing spondylitis, OA & spondyl...

Indication: Symptomatic treatment of nausea & vertigo due to Meniere's disease & other labyrinthine disturbances, ...

Indication: Relief of fever associated w/ cold & flu, pain eg, teething, toothache, earache, sore throat, headache, mi...

Indication: Relief of fever & mild to moderate pain including headache, dental pain, post-op pain, dysmenorrhoea; musc...

Indication: Rheumatic fever, RA, allergic diseases, nephritic syndrome, bronchial asthma & other corticosteroid-indica...

1  /  14
Editor's Recommendations
Most Read Articles
Audrey Abella, 15 Aug 2018
Supervised aerobic-strength training improved cognitive and motor functions among elderly individuals with mild cognitive impairment (MCI), according to studies presented at AAIC 2018.
12 May 2019
A consistent association exists between perinatal maternal depressive symptoms and child brain development assessed 10 years later, suggests a recent study.
02 Sep 2016
Results of a study show that patients with relapsing-remitting multiple sclerosis may benefit from the new sphingosine 1-phosphate 1 inhibitor drug amiselimod.